Why One-Time Aneurysm Screening Targets Older Men Who Ever Smoked

A screening recommendation that seems to leave you out is often doing something more precise than it looks. The US Preventive Services Task Force recommends a single abdominal ultrasound for abdominal aortic aneurysm (AAA) and reserves its grade B, its clearest endorsement here, for one group only: men aged 65 to 75 who have ever smoked. Everyone else receives a weaker statement. The reason is not that other people cannot form an aneurysm. It is that the randomized evidence measuring whether early detection saves lives was gathered almost entirely in that one group, and a grade letter tracks the evidence, not the disease.

Key points#

• The grade B applies only to men 65 to 75 who ever smoked, because four randomized trials measured net benefit there and almost nowhere else.
• Pooled trials showed about a 35 percent drop in AAA-related death, with roughly 305 men screened to prevent one such death.
• Smoking is the strongest driver of aneurysm formation, growth, and rupture, so benefit concentrates in smokers.
• Never-smoking men receive a grade C (decide case by case), and lower-risk women a grade D (against) or grade I (insufficient evidence).
• The counterweight is real harm: more elective operations, overdiagnosis of small aneurysms, and the risk that surgery itself carries.

What a grade letter actually measures#

A common misreading is that the Task Force is ranking diseases by importance. It is not. It grades a specific test, given to a specific population, and asks two questions: how certain are we, and how large is the net benefit once harms are subtracted. That produces a short vocabulary. Grade B means moderate certainty of a moderate net benefit, offer the service. Grade C means moderate certainty of a small net benefit, so offer it selectively rather than by default. Grade D means moderate certainty that harms outweigh benefit, a recommendation against. Grade I means the evidence is too thin to weigh the two sides at all. The 2019 statement, published in JAMA, hands each of those four verdicts to a different slice of older adults. Following why they diverge takes you on a tour of where the trial data is dense, thin, or absent.

Reading the trial evidence#

Four large randomized controlled trials anchor the recommendation: MASS, Viborg County, Chichester, and Western Australia. Together they enrolled tens of thousands of people, but the Task Force is candid that their randomized signal comes almost entirely from men aged 65 to 75. Pooled across the trials, inviting these men to a one-time scan cut AAA-related mortality by about 35 percent, a statistically significant result. Translated into an everyday number, roughly 305 men had to be screened to prevent one death from a ruptured aneurysm. For a preventive test, that is a genuine, measurable payoff.

Two facts temper the enthusiasm without erasing it. The pooled data showed no change in all-cause mortality, meaning screening reshapes the recorded cause of death more clearly than it moves a man's overall odds of dying. And the benefit clusters in smokers. The recommendation names smoking as the strongest single predictor of whether an aneurysm forms, how fast it grows, and whether it ruptures, and it follows a dose pattern, with heavier and longer smoking carrying more risk. An AAA is defined as an aortic diameter of 3.0 cm or more, and rupture is often fatal, with death rates reported as high as 81 percent. When a lethal event is packed so tightly into one risk profile, that profile is where screening arithmetic turns positive.

Following the risk gradient down#

The rest of the grade map is what happens when you hold that same test steady and lower the underlying risk.

Consider men 65 to 75 who never smoked. They can still develop an aneurysm, but their baseline rate is lower, and a lower rate shrinks the absolute gain from finding disease early. Population estimates put AAA prevalence in older men somewhere between 1.2 and 3.3 percent, and because smoking dominates the risk, never-smokers sit toward the bottom of that band. The ultrasound is not the weak link: a one-time scan reads at 94 to 100 percent sensitivity and 98 to 100 percent specificity. The problem is purely one of yield. In a low-prevalence group the same excellent test surfaces fewer true aneurysms per thousand scans while the harms hold constant. Hence a grade C, a nudge to decide individually, weighing factors such as family history, rather than a blanket recommendation.

Women split into two categories, and the split is instructive. A woman who never smoked and has no family history receives a grade D, an active recommendation against routine screening, because AAA is markedly rarer in that profile and the harms of scanning a low-risk group outweigh the slim chance of benefit. Chichester, the one trial that enrolled women, reported AAA prevalence near 1.3 percent in women against 7.6 percent in men.

A woman who ever smoked or has a family history of AAA receives a grade I, insufficient evidence. This is honesty, not dismissal. The trials were built around men, so there is no adequately powered randomized data on whether screening higher-risk women helps or harms. The biology may not transfer either. The recommendation notes that in women aneurysms tend to rupture at smaller diameters and older ages, and that surgical repair carried higher operative mortality. Because the diameter thresholds that trigger repair were derived largely from men, a program cut to the male pattern could under-treat higher-risk women at the sizes where they actually rupture while still handing them the harms of intervention. The trials simply were not designed to answer that question.

The harms on the other side of the ledger#

None of the caution makes sense without the second half of the balance. Screening everyone would look safer only if the test were consequence-free, and it is not. A detected aneurysm launches surveillance scans, worry, and sometimes surgery. Across the trials the screened groups underwent roughly 40 percent more elective operations, and elective repair carries its own operative risk. Overdiagnosis of small aneurysms that would never have burst, plus the overtreatment that can follow, is exactly why the Task Force declines to screen groups where the true-positive yield is low. A grade B for higher-risk men and a grade D for lower-risk women are not opposite instincts. They are the same rule applied twice: screen where the benefit clears the harm, and hold back where it does not.

Read this way, the recommendation is less a verdict on whether you deserve attention and more a map of where the evidence is solid, thin, or missing entirely.